Coherus Oncology (CHRS) Goodwill & Intangibles (2016 - 2025)
Coherus Oncology (CHRS) has disclosed Goodwill & Intangibles for 12 consecutive years, with $46.2 million as the latest value for Q4 2025.
- Quarterly Goodwill & Intangibles fell 13.81% to $46.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.2 million through Dec 2025, down 13.81% year-over-year, with the annual reading at $46.2 million for FY2025, 13.81% down from the prior year.
- Goodwill & Intangibles hit $46.2 million in Q4 2025 for Coherus Oncology, down from $49.5 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $71.7 million in Q4 2023 to a low of $3.6 million in Q1 2021.
- Historically, Goodwill & Intangibles has averaged $29.2 million across 5 years, with a median of $26.1 million in 2022.
- Biggest five-year swings in Goodwill & Intangibles: surged 1108.45% in 2023 and later decreased 25.15% in 2024.
- Year by year, Goodwill & Intangibles stood at $3.6 million in 2021, then surged by 66.46% to $5.9 million in 2022, then soared by 1108.45% to $71.7 million in 2023, then fell by 25.15% to $53.6 million in 2024, then dropped by 13.81% to $46.2 million in 2025.
- Business Quant data shows Goodwill & Intangibles for CHRS at $46.2 million in Q4 2025, $49.5 million in Q3 2025, and $52.3 million in Q2 2025.